HIGHLIGHTS Discovered Over 100 New Compounds Identified in 40 different therapeutic classes Predictive Technology up to 85% accuracy in bioactive compound selection Discovery of New Chemical Entities which Offer Broad Patent Protection Successfully Implemented Forward Engineering™ With Big Pharma, Biotech, Animal Health, and Nutraceutical Companies

Medisyn's proprietary technology, called Forward Engineering™, is a unique in silico prediction platform capable of quickly designing new or improved patentable molecules from pre-specified properties.   The core competency of our disruptive technology has the ability to identify novel lead candidates that are structurally very different from the starting point and that belong to diverse new chemical classes. The technology can identify molecules that possess desired properties (such as efficacy in treating a disease) and accurately assess the drug-like characteristics (e.g., safety, efficacy, ADME/Toxicity, potency) of novel compounds.   With this technology, Medisyn can do in weeks what traditionally takes years to accomplish.   Medisyn's unique methodology and these supporting data have been published in over 100 peer reviewed journal articles.

Medisyn's discovery process works by creating a "digital fingerprint" of therapeutic activity for a specific disease which is then used to search chemical libraries for compounds with similar or identical fingerprints.   Once a match has been made, the compounds are submitted for lab testing to confirm activity. Medisyn has identified potent compounds in as little as eight weeks and currently has 40 active projects in 22 therapeutic areas including cancer, AIDS and Alzheimer's.  

Medisyn's core technology is based on application of mathematical topology to chemical characterization and prediction.   A training set of molecules is used to construct a model for the attributes of interest, and the model then predicts attributes of other chemical structures based on topological similarities.   The approach is distinct from, but complementary with, standard computational chemistry, structure-based drug design, and medicinal chemistry methods.   The key differentiating benefit is the technology's core ability to discover New Chemical Entities (NCEs). NCEs are drug leads in new chemical classes offering potentially greater disease treating benefits and "first-in-class" market opportunities. This is an extraordinarily difficult task with conventional approaches. The mathematics underlying the Medisyn technology, topology, is also the basis for string theory in physics, electrical engineering applications, and other fields.